Electromed vs Pulmonx
ELMD and LUNG side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELMD and LUNG compare
Electromed is the larger company, worth 1.7 times as much as Pulmonx ($203M against $123M).
Electromed grew revenue faster over the last twelve months (14.1% versus −3.2% for Pulmonx).
Electromed keeps more of each dollar of sales as profit, with a net margin of 15.8% compared with −47.9% at Pulmonx.
Electromed scores higher on the StockData Score (21 against 6 for Pulmonx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELMD | LUNG |
|---|---|---|
| Size and price | ||
| Market cap | $203M | $123M |
| Share price | $24.32 | $2.86 |
| Change, 1 year | −4.2% | 45.9% |
| Change, 5 years | 106% | −91.7% |
| Beta (5Y) | 0.49 | 1.73 |
| Employees | 197 | 296 |
| StockData Score | ||
| Total score | 21 (better) | 6 |
| Valuation score | 5 (better) | 2 |
| Growth score | 5 (better) | 2 |
| Performance score | 5 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.6× | – |
| P/S | 2.7× | 1.4× (better) |
| P/B | 3.9× | 3.6× (better) |
| EV/EBITDA | 12.8× | – |
| P/FCF | 23.4× | – |
| PEG | 0.33 | – |
| FCF yield | 4.3% (better) | −20.8% |
| Fair value | $33.69 | $4.74 |
| Margin of safety | 27.8% | 39.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.1% (better) | −3.2% |
| Revenue growth, 5Y average | 15.6% | 22.6% (better) |
| Net income growth (TTM) | 45.5% | – |
| EPS growth (TTM) | 48.4% | – |
| EPS growth, 5Y average | 36.9% | – |
| Profitability | ||
| Gross margin | 79.0% (better) | 77.4% |
| Operating margin | 19.5% (better) | −44.4% |
| Net margin | 15.8% (better) | −47.9% |
| FCF margin | 11.5% (better) | −28.8% |
| Return on equity | 24.5% (better) | −90.3% |
| Return on invested capital | 34.3% (better) | −156% |
| Financial health | ||
| Debt / equity | 0.00 | 1.11 (better) |
| Interest coverage | – | −9.4× |
| Current ratio | 7.19 (better) | 4.05 |
| Altman Z-score | 17.69 (better) | −5.75 |
| Piotroski F-score | 8 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 3.6% | – |
| Shareholder yield | 3.6% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 55.6% | 61.0% |
| Held by insiders | 11.4% | 16.6% |
| Insider net buying, 12 months | −$2.2M | −$548K (better) |
| Short interest, % of float | 2.4% | 2.2% |
Go deeper
- ELMD stock overview
- ELMD income statement
- ELMD valuation and score
- LUNG stock overview
- LUNG income statement
- LUNG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.